2. Protein Tyrosine Kinase/RTK Immunology/Inflammation NF-κB Metabolic Enzyme/Protease
  3. VEGFR Toll-like Receptor (TLR) COX NO Synthase NF-κB MMP
  4. Guluronic acid sodium

Guluronic acid sodium  (Synonyms: G2013 sodium)

Cat. No.: HY-N7700A Purity: 98.0%
COA
SDS
Handling Instructions Technical Support

Guluronic acid (G2013) sodium is an orally active oxidative stress regulator and anti-inflammatory agent that exerts pharmacological effects by down-regulating various pro-inflammatory and oxidative stress-related genes (such as TLR4, NF-κB, iNOS, etc.) and inhibiting the activities of COX-2, MMPs and VEGF. Low-dose Guluronic acid sodium up-regulates the expression of immunoregulatory genes SHIP1 and SOCS1, thereby effectively inhibiting cancer-related inflammation, tumor angiogenesis, cell adhesion and metastasis, while reducing the accumulation of immunosuppressive cells. Guluronic acid sodium significantly prolongs the survival time of tumor-bearing hosts within a concentration range without direct cytotoxicity, demonstrating favorable safety. Guluronic acid sodium has involved in the research of multiple sclerosis, ankylosing spondylitis, breast cancer and other inflammatory diseases.

For research use only. We do not sell to patients.

Guluronic acid sodium

Guluronic acid sodium Chemical Structure

Size Price Stock Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in Water
ready for reconstitution
 In-stock
Solution
10 mM * 1 mL in Water In-stock
Solid
5 mg In-stock
10 mg In-stock
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of Guluronic acid sodium:

Guluronic acid sodium Related Antibodies

Top Publications Citing Use of Products

1 Publications Citing Use of MCE Guluronic acid sodium

View All VEGFR Isoform Specific Products:

View All Isoforms
VEGFR1/Flt-1 VEGFR2/KDR/Flk-1 VEGFR3/Flt-4

View All Toll-like Receptor (TLR) Isoform Specific Products:

View All Isoforms
TLR3 TLR8 TLR9 TLR2 TLR4 TLR7 TLR1 TLR6

View All COX Isoform Specific Products:

View All Isoforms
COX COX-1 COX-2 COX-3

View All NO Synthase Isoform Specific Products:

View All Isoforms
nNOS iNOS eNOS

View All NF-κB Isoform Specific Products:

View All Isoforms
NF-κB NF-κB1/p50 RelA/p65 RelB c-Rel

View All MMP Isoform Specific Products:

View All Isoforms
MMP-1 MMP-2 MMP-3 MMP-8 MMP-9 MMP-13 MMP-14 MMP-17 ADAM10 ADAM17 MMP-7 MMP-12 MMP-10 MMP ADAM8 MMP-19

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Guluronic acid (G2013) sodium is an orally active oxidative stress regulator and anti-inflammatory agent that exerts pharmacological effects by down-regulating various pro-inflammatory and oxidative stress-related genes (such as TLR4, NF-κB, iNOS, etc.) and inhibiting the activities of COX-2, MMPs and VEGF. Low-dose Guluronic acid sodium up-regulates the expression of immunoregulatory genes SHIP1 and SOCS1, thereby effectively inhibiting cancer-related inflammation, tumor angiogenesis, cell adhesion and metastasis, while reducing the accumulation of immunosuppressive cells. Guluronic acid sodium significantly prolongs the survival time of tumor-bearing hosts within a concentration range without direct cytotoxicity, demonstrating favorable safety. Guluronic acid sodium has involved in the research of multiple sclerosis, ankylosing spondylitis, breast cancer and other inflammatory diseases[1][2][3][4].

IC50 & Target

MMP-9

 

MMP-2

 

COX-2

 

TLR4

 

iNOS

 

In Vitro

Guluronic acid sodium (G2013) (5-25 μg/well; 18 h following 4 h LPS pre-incubation) significantly suppresses LPS-induced mRNA expression of SOD2, GPX1, GST, and MPO in healthy human PBMCs; at 25 μg/well, it additionally significantly suppresses LPS-induced CAT and iNOS mRNA expression in these cells, while the 5 μg/well dose does not produce statistically significant reductions in CAT or iNOS mRNA expression[1].
Guluronic acid sodium (5 μg/well-15 μg/well; 24 h) in untreated HEK-Blue hTLR4 cells, at 5 μg/well (24 h) significantly reduces TLR4, MyD88, and NF-κB gene expression, and significantly increases SHIP1 and SOCS1 gene expression; at 15 μg/well (24 h), it significantly reduces TLR4, MyD88, and SOCS1 gene expression, with non-significant changes to SHIP1 and NF-κB[2].
Guluronic acid sodium (200 ng/ml-125 μg/ml; 24 h) has no cytotoxic effect on HEK-Blue hTLR4 cells at concentrations below 125 μg/ml, and exhibits an IC50 of 125 μg/ml for 24 h treatment[2].
Guluronic acid sodium (25-500 μg/ml; 48 h) dose-dependently inhibits the activity of MMP2 (22-31% reduction) and MMP9 (28-44% reduction) in 4T1 murine breast cancer cells[3].
Guluronic acid sodium (25-500 μg/ml; 24 h co-incubation) reduces LPS-induced PG2E production by ~66% in J774 murine macrophage cells[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Guluronic acid sodium Related Antibodies

Cell Cytotoxicity Assay[3]

Cell Line: HEK-Blue hTLR4 cells
Concentration: 200 ng/ml, 1 μg/ml, 5 μg/ml, 25 μg/ml, 125 μg/ml
Incubation Time: 24 h
Result: Showed no cytotoxic effect at concentrations below 125 μg/ml. Reduced cell viability to ~60% of the control at 125 μg/ml. Reached an IC50 of 125 μg/ml after 24 h treatment.

Real Time qPCR[3]

Cell Line: HEK-Blue hTLR4 cells (untreated condition)
Concentration: 5 μg/well (low dose); 15 μg/well (high dose)
Incubation Time: 24 h
Result: Decreased TLR4 gene expression by 65% (low dose) and 41% (high dose), compared to control.
Decreased MyD88 gene expression by 82% (low dose) and 47% (high dose), compared to control.
Increased SHIP1 gene expression by 62% (low dose) and decreased it by 27% (high dose, non-significant), compared to control. Increased SOCS1 gene expression by 72% (low dose) and decreased it by 29% (high dose), compared to control.
Decreased NF-κB gene expression by 69% (low dose) and 49% (high dose, non-significant), compared to control.

ELISA Assay[4]

Cell Line: J774 murine macrophage cells
Concentration: 25, 250, 500 μg/ml
Incubation Time: 24 h (co-incubated with LPS)
Result: Reduced PGE2 levels by ~66% across all tested concentrations compared to LPS-only treated cells.
In Vivo

Guluronic acid (G2013) sodium reduces disease severity, delays onset, and decreases incidence of experimental autoimmune encephalomyelitis in mice[1].
Guluronic acid (50 mg/kg; i.p.; every 2 days; day 6 to day 26 post-tumor inoculation) sodium and Guluronic acid (50 μg/ml; in vitro 48-hour pre-treatment of 4T1 cells) sodium inhibits cancer-related inflammation, reduces tumor growth by up to ~94.1%, eliminates metastasis in pre-treated cells, and prolongs survival in syngeneic murine breast cancer models[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Breast cancer model in BALB/c (female, 6-8 weeks old, 18-20 g, syngeneic breast cancer model induced by 5×105 4T1 cell injection into mammary fat pad)[4]
Dosage: 50 mg/kg (therapeutic group); 50 μg/ml (cell line pre-treated group)
Administration: i.p.; every 2 days; day 6 to day 26 post-tumor inoculation (therapeutic group); in vitro pre-treatment of 4T1 cells before inoculation (cell line pre-treated group)
Result: Reduced tumor volume by ~61.4% (therapeutic group) and ~94.1% (cell line pre-treated group) on day 30 post-inoculation compared to controls.
Exhibited metastasis incidence of 80% lung, 60% lymph node, and 20% liver (therapeutic group); showed no detectable metastasis in any organs (cell line pre-treated group).
Reduced lung metastatic area to ~5% per section (therapeutic group) and 0% (cell line pre-treated group) compared to ~15% in controls.
Lowered serum levels of IL-1β and IL-6 significantly in both groups; left TNF-α levels unchanged.
Reduced white blood cell count and granulocyte-to-lymphocyte ratio in both groups.
Reduced frequency of regulatory T cells (Treg) significantly in tumor tissue and lymph nodes (therapeutic group).
Reduced myeloid-derived suppressor cells (MDSC) significantly in tumor tissue and spleen (therapeutic group).
Reduced tumor angiogenesis by ~59.8% (therapeutic group) and ~91.1% (cell line pre-treated group) compared to controls.
Lowered tumor tissue mRNA expression of COX-2, MMP2, MMP9, and VEGF significantly in both groups compared to controls.
Prolonged survival significantly, with 100% of mice in the cell line pre-treated group surviving up to day 90, and higher survival rate in the therapeutic group than in controls.
Molecular Weight

216.12

Formula

C6H9NaO7
Appearance

Solid

Color

White to light yellow

SMILES

O=C[C@@H]([C@@H]([C@H]([C@@H](C(O[Na])=O)O)O)O)O
Structure Classification
Initial Source
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

4°C, sealed storage, away from moisture and light

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

Solvent & Solubility
In Vitro: 

H2O : 62.5 mg/mL (289.19 mM; ultrasonic and warming and heat to 60°C)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 4.6271 mL 23.1353 mL 46.2706 mL
5 mM 0.9254 mL 4.6271 mL 9.2541 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Calculation results:
Working solution concentration: mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).
Purity & Documentation

Purity: 98.0%

SDS (252 KB)

COA (249 KB) HNMR (246 KB) MS (68 KB)

Handling Instructions (2659 KB)
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
H2O 1 mM 4.6271 mL 23.1353 mL 46.2706 mL 115.6765 mL
5 mM 0.9254 mL 4.6271 mL 9.2541 mL 23.1353 mL
10 mM 0.4627 mL 2.3135 mL 4.6271 mL 11.5676 mL
15 mM 0.3085 mL 1.5424 mL 3.0847 mL 7.7118 mL
20 mM 0.2314 mL 1.1568 mL 2.3135 mL 5.7838 mL
25 mM 0.1851 mL 0.9254 mL 1.8508 mL 4.6271 mL
30 mM 0.1542 mL 0.7712 mL 1.5424 mL 3.8559 mL
40 mM 0.1157 mL 0.5784 mL 1.1568 mL 2.8919 mL
50 mM 0.0925 mL 0.4627 mL 0.9254 mL 2.3135 mL
60 mM 0.0771 mL 0.3856 mL 0.7712 mL 1.9279 mL
80 mM 0.0578 mL 0.2892 mL 0.5784 mL 1.4460 mL
100 mM 0.0463 mL 0.2314 mL 0.4627 mL 1.1568 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Guluronic acid sodium Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Guluronic acidG2013G 2013G-2013VEGFRToll-like Receptor (TLR)COXNO SynthaseNF-κBMMPVascular endothelial growth factor receptorCyclooxygenaseNitric oxide synthasesNOSNuclear factor-κBNuclear factor-kappaBMatrix metalloproteinasesGSTGPX1CATTLR4iNOSSOD2MyD88MPOperipheral blood mononuclear cellsInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Guluronic acid sodium
Cat. No.:
HY-N7700A
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (252 KB) Français - FR (252 KB) Deutsch - DE (252 KB) Norwegian - NO (252 KB) Español - ES (252 KB) Swedish - SV (252 KB) Italian - IT (252 KB) Korean - KR (252 KB) Portuguese - PT (252 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.